FinTechFunding

Immutep: Shares positive data from phase 2b AIPAC trial

Immutep Shares positive data from phase 2b AIPAC trial

  • Immutep (IMM) sees a significant increase in innate and adaptive immune response biomarkers in its phase IIb AIPAC trial
  • The trial evaluated efti combined with paclitaxel chemotherapy compared to a placebo group in 227 patients with HER2-negative/HR-positive metastatic breast cancer
  • IMM says the higher immune response in efti patients compared to placebo patients confirms efti is activating the immune system and improving overall survival
  • The company is a globally active biotechnology company that is a leader in developing LAG-3 related immunotherapeutic products
  • The company is trading 7.58 per cent higher at 35.5 cents
Previous article
Intigriti: Raises Over €21.13M in Series B Funding
Next article
Elixir Energy: Completes Tim-2 well in Mongolia
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

FinTech

NatWest Group Strengthens Free Investment Guidance Programme

New initiative aims to educate more customers on investing.Highlights: NatWest Group expands free investment guidance programme.Initiative targets educating...
FinTech

Tether Launches New Stablecoin Wallet to Enhance User Experience

This innovative platform aims to improve accessibility for crypto users.Highlights: Tether has introduced a new stablecoin wallet.The wallet...
FinTech

FCA Strengthens Money Laundering Combat with Synthetic Dataset

New collaboration aims to enhance detection capabilities against financial crime.Highlights: FCA partners with Turing Institute to combat money...
FinTech

Spektr Strengthens Compliance Efforts with $20M Funding

Fintech startup Spektr secures $20 million for AI-driven compliance solutions.Highlights: Spektr raises $20 million to enhance its AI...